Dan Massey

Dan Massey is affiliated with the University of Colorado Boulder in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with specific subfields including Endocrinology, Diabetes and Metabolism, Genetics, Pulmonary and Respiratory Medicine, Small Animals, and Nephrology.

Their scholarly work focuses on several main topics: Human-Animal Interaction Studies, Diabetes Treatment and Management, Veterinary Medicine and Surgery, Pancreatic function and diabetes, Chronic Kidney Disease and Diabetes, Gut microbiota and health, and Clostridium difficile and Clostridium perfringens research.

Frequent coauthors collaborating with Massey include Aashish R. Jha, Justin Shmalberg, Jirayu Tanprasertsuk, Ryan W. Honaker, and William G. Herrington. Their work is commonly published in notable venues such as the New England Journal of Medicine, Research Square, PLoS ONE, Journal of Clinical Oncology, and Breast Cancer Research.

• Empagliflozin in Patients with Chronic Kidney Disease (2022), New England Journal of Medicine
• Characterization of gut microbiomes of household pets in the United States using a direct-to-consumer approach (2020), PLoS ONE
• Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (2024), New England Journal of Medicine
• Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations (2023), Journal of Clinical Oncology
• XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease (2023), Breast Cancer Research

Massey's research covers a diverse range of topics, reflecting interdisciplinary investigation into both human and veterinary medicine. Their work on diabetes management and chronic kidney disease contributes to understanding treatment options in clinical settings. Additionally, studies related to gut microbiota and health investigate the microbial ecosystems in household pets, contributing to the field of human-animal interaction studies.

The emphasis on endocrinology and metabolism is seen in their publications that explore the effects of medications such as empagliflozin on kidney disease outcomes. The inclusion of genetic and pulmonary/respiratory medicine topics highlights a broad biological and clinical investigative scope.

Overall, Dan Massey's publication record and collaborations indicate active engagement in clinical and translational research with a focus on diseases that affect both humans and animals.